Objective To generate estimates of comparative clinical effectiveness for interventions used
in the treatment of anogenital warts (AGWs) through the systematic review, appraisal and …

To prevent cervical cancer, a governmentfunded vaccination programme against human
papillomavirus (HPV) infection started in New Zealand in 2008. After an initial catch-up …

Imiquimod, an immune response modifier, has been demonstrated to be safe and effective
in the treatment of external genital and perianal warts caused by human papillomavirus …

Genital warts caused by human papillomavirus infection are encountered commonly in
primary care. Evidence guiding treatment selection is limited, but treatment guidelines …

The monetary and personal costs to society of human papillomavirus (HPV) infection are
enormous. In order to make a comparison of different treatment methods we reviewed the …

Conventional therapies for human papillomavirus infection aim to remove clinically apparent
lesions, while latent infection may remain, representing a threat for transmission and …

Background We assessed the effectiveness of the quadrivalent human papillomavirus
vaccine (qHPV) vaccination program in Manitoba, Canada, in reducing incident anogenital …

Introduction Several therapeutic options are available to manage anogenital warts (AGWs).
However, no hierarchy of treatments is provided in the latest European and American …

To determine the value of combining interferon with standard local therapy in the treatment
of human papillomavirus infection, 97 patients with anogenital warts were randomized to a …

Background Benign external genital and perianal warts (condylomata acuminata) are
disfiguring, displeasing skin tumours caused by human papillomavirus that may vitally …